Therapeutic benefits of Nanoparticles in Stroke
Stroke represents one of the major causes of death and disability worldwide, for which no effective treatments are available. The thrombolytic drug alteplase (tissue plasminogen activator or tPA) is the only treatment for acute ischemic stroke but its use is limited by several factors including shor...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2015-05-01
|
| Series: | Frontiers in Neuroscience |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fnins.2015.00182/full |
| _version_ | 1819153290989928448 |
|---|---|
| author | Stavros ePanagiotou Sikha eSaha |
| author_facet | Stavros ePanagiotou Sikha eSaha |
| author_sort | Stavros ePanagiotou |
| collection | DOAJ |
| description | Stroke represents one of the major causes of death and disability worldwide, for which no effective treatments are available. The thrombolytic drug alteplase (tissue plasminogen activator or tPA) is the only treatment for acute ischemic stroke but its use is limited by several factors including short therapeutic window, selective efficacy and subsequent haemorrhagic complications. Numerous preclinical studies have reported very promising results using neuroprotective agents but they have failed at clinical trials because of either safety issues or lack of efficacy. The delivery of many potentially therapeutic neuroprotectants and diagnostic compounds to the brain is restricted by the blood-brain barrier (BBB). Nanoparticles (NPs), which can readily cross the BBB without compromising its integrity, have immense applications in the treatment of ischemic stroke. In this review, potential uses of NPs will be summarized for the treatment of ischemic stroke. Additionally, an overview of targeted NPs will be provided, which could be used in the diagnosis of stroke. Finally, the potential limitations of using NPs in medical applications will be mentioned. Since the use of NPs in stroke therapy is now emerging and is still in development, this review is far from comprehensive or conclusive. Instead, examples of NPs and their current use will be provided, as well as the potentials of NPs in an effort to meet the high demand of new therapies in stroke. |
| first_indexed | 2024-12-22T15:02:51Z |
| format | Article |
| id | doaj.art-7bb1123306e5492f99718d8aa3496f9d |
| institution | Directory Open Access Journal |
| issn | 1662-453X |
| language | English |
| last_indexed | 2024-12-22T15:02:51Z |
| publishDate | 2015-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neuroscience |
| spelling | doaj.art-7bb1123306e5492f99718d8aa3496f9d2022-12-21T18:22:05ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2015-05-01910.3389/fnins.2015.00182139622Therapeutic benefits of Nanoparticles in StrokeStavros ePanagiotou0Sikha eSaha1University of LeedsUniversity of LeedsStroke represents one of the major causes of death and disability worldwide, for which no effective treatments are available. The thrombolytic drug alteplase (tissue plasminogen activator or tPA) is the only treatment for acute ischemic stroke but its use is limited by several factors including short therapeutic window, selective efficacy and subsequent haemorrhagic complications. Numerous preclinical studies have reported very promising results using neuroprotective agents but they have failed at clinical trials because of either safety issues or lack of efficacy. The delivery of many potentially therapeutic neuroprotectants and diagnostic compounds to the brain is restricted by the blood-brain barrier (BBB). Nanoparticles (NPs), which can readily cross the BBB without compromising its integrity, have immense applications in the treatment of ischemic stroke. In this review, potential uses of NPs will be summarized for the treatment of ischemic stroke. Additionally, an overview of targeted NPs will be provided, which could be used in the diagnosis of stroke. Finally, the potential limitations of using NPs in medical applications will be mentioned. Since the use of NPs in stroke therapy is now emerging and is still in development, this review is far from comprehensive or conclusive. Instead, examples of NPs and their current use will be provided, as well as the potentials of NPs in an effort to meet the high demand of new therapies in stroke.http://journal.frontiersin.org/Journal/10.3389/fnins.2015.00182/fullBlood-Brain BarrierNanoparticlesDrug deliveryischemic strokediagnostic tool |
| spellingShingle | Stavros ePanagiotou Sikha eSaha Therapeutic benefits of Nanoparticles in Stroke Frontiers in Neuroscience Blood-Brain Barrier Nanoparticles Drug delivery ischemic stroke diagnostic tool |
| title | Therapeutic benefits of Nanoparticles in Stroke |
| title_full | Therapeutic benefits of Nanoparticles in Stroke |
| title_fullStr | Therapeutic benefits of Nanoparticles in Stroke |
| title_full_unstemmed | Therapeutic benefits of Nanoparticles in Stroke |
| title_short | Therapeutic benefits of Nanoparticles in Stroke |
| title_sort | therapeutic benefits of nanoparticles in stroke |
| topic | Blood-Brain Barrier Nanoparticles Drug delivery ischemic stroke diagnostic tool |
| url | http://journal.frontiersin.org/Journal/10.3389/fnins.2015.00182/full |
| work_keys_str_mv | AT stavrosepanagiotou therapeuticbenefitsofnanoparticlesinstroke AT sikhaesaha therapeuticbenefitsofnanoparticlesinstroke |